{"brief_title": "Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma", "brief_summary": "Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.", "condition": ["Melanoma", "Neoplasm Metastasis"], "intervention_type": ["Drug"], "intervention_name": ["CC 5013"], "criteria": "- Understand and voluntarily sign an informed consent form. - Able to adhere to the study visit schedule and other protocol requirements. - Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy. - Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug. - Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "CC5013", "mesh_term": ["Melanoma", "Neoplasm Metastasis", "Lenalidomide", "Thalidomide"], "id": "NCT00055562"}